We found significantly lower signal intensities of CD81 (****) positive serum-derived EVs comparing AML with ALL derived EVs and significantly lower signal intensities of CD9 (*), of CD63 (****), of CD81 (*), of CD42a (****), of CD62P (****) positive serum-derived EVs comparing AML with CLL derived EVs with results normalized to IC leukemic cell counts. This evidence concerns the gene GP9 and acute lymphoblastic leukemia.